Answers are grounded in this paper and cite their sources.
Background Urinary tract infections (UTIs) are among the most common bacterial infections of childhood, and rising antibiotic resistance complicates empirical therapy. Using culture-positive urine specimens, we evaluated the distribution of uropathogens, their phenotypic antibiotic resistance, and six-year changes in resistance at a tertiary hospital. Methods In this retrospective cross-sectional study, records of children younger than 18 years with a positive urine culture between January 2019 and December 2024 were analysed. The analysis was specimen (isolate)-based; a proxy patient-level sensitivity analysis (patients approximated by date of birth and sex, first isolate retained) was also performed. Identification and susceptibility testing used an automated system (Vitek 2 Compact) interpreted by the CLSI criteria in force each year; intermediate isolates were classified as resistant. Following a data audit, duplicate antibiogram entries were resolved to a single interpretation per specimen-antibiotic combination. Extended-spectrum beta-lactamase (ESBL) production was determined phenotypically and analysed only among isolates with a valid recorded result. Yearly trends were examined with the Cochran–Armitage test with false-discovery-rate adjustment and were interpreted only for antibiotics with consistently high testing coverage; associations with ESBL positivity and multidrug resistance (MDR) were assessed by logistic regression adjusted for sex, age, year and care setting. Results A total of 10,348 isolates were analysed; the specimens originated predominantly from inpatient wards (57.5%) and the emergency department (32.9%). Escherichia coli was the most frequent pathogen (58.3%), followed by Klebsiella spp. (18.1%) and Proteus spp. (6.7%). In E. coli, resistance was highest to ampicillin (62.5%, 95% CI 61.3–63.7) and lowest to imipenem (0.3%), meropenem (0.4%) and amikacin (1.6%). Phenotypic ESBL positivity was 30.7% among the 3,879 E. coli isolates (64.3% of all E. coli) with a valid recorded ESBL result. Among antibiotics with consistently high testing coverage, resistance rose from 2019 to 2024 for ciprofloxacin (14.7% to 44.5%) and ampicillin (58.8% to 68.9%) (adjusted p < 0.001), whereas amikacin and carbapenem resistance remained low and stable. Because ESBL testing coverage increased from 4.5% to 98.7% of E. coli isolates over the period, the temporal course of ESBL positivity could not be evaluated reliably. The MDR rate in E. coli was 42.1% (52.9% in 2024); male sex, the 12–60-month age group, calendar year and inpatient setting showed adjusted associations with ESBL positivity and MDR. Results were materially unchanged in the proxy patient-level analysis. Conclusions In this predominantly hospitalized and referred pediatric population, resistance to ampicillin and trimethoprim-sulfamethoxazole was high, whereas carbapenems, amikacin and nitrofurantoin retained low resistance, and ciprofloxacin resistance increased markedly. These laboratory surveillance findings are not generalisable to community settings; treatment decisions should follow clinical guidelines and local antimicrobial stewardship policies informed by regularly updated, setting-specific antibiograms.
No takes yet. Share an insight, caveat, or question.
Erdoğan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: